Why tocilizumab could be an effective treatment for severe COVID-19?
University of Science and Technology of China · Hefei National Center for Physical Sciences at Nanoscale
Abstract
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and…
Citation impact
- FWCI
- 11.56
- Percentile
- 100%
- References
- 16
Authors
3- BFBinqing FuCorresponding
University of Science and Technology of China, Hefei National Center for Physical Sciences at Nanoscale
- XXXiaoling Xu
University of Science and Technology of China
- HWHaiming Wei
University of Science and Technology of China, Hefei National Center for Physical Sciences at Nanoscale
Topics & keywords
- Tocilizumab
- Cytokine storm
- ARDS
- Medicine
- Pneumonia
- Cytokine release syndrome
- Diffuse alveolar damage
- Immune system
- Good health and well-being
Funding
- NNNational Natural Science Foundation of ChinaAwards: 81788101, COVID-19, 81922028
- CAChinese Academy of SciencesAward: 81788101
- YIYouth Innovation Promotion Association of the Chinese Academy of SciencesAward: 2019442
- UOUniversity of Science and Technology of China
- YIYouth Innovation Promotion Association